Sotheby’s (BID) is gearing up for what could be its biggest auction in history. The vast collection of artwork and sculptures is from billionaire real estate developer and former Sotheby's owner, A. Alfred Taubman, who passed away earlier this year. The auction flaunts paintings from legendary artists like Rothko, Modigliani and Picasso. With 500 pieces in the collection, the auction could be worth over a half a billion dollars. 'The contemporary art that Mr. Taubman collected is exceptional,’ said Alexander Rotter, sr. vice president & co-head of contemporary art worldwide at Sotheby's. ‘It's highlighted by two amazing [Mark] Rothko paintings – one from 1952 and one from 1962. Both of them are expected to sell between $20-$30 million.’ As for who is scooping up paintings with 8-figure price tags -- it all comes back to one thing. 'Everyone who has the money can be a buyer,’ Rotter added. But it's not just paintings from the world's most famous artists. The Taubman collection includes a host of statues and sculptures. 'He collected lots of wonderful sculptures from Jean Arp and Ignazio Jacometti,’ Rotter said. ‘The variety and the scope of his collecting went two dimensional, three dimensional - in every direction.' TheStreet’s Scott Gamm reports from New York.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.